FDA Recalls Desk — Oct 22: 10 Class II Actions, No Class I Flags

Today's FDA recall feed carries ten entries, all classified Class II — no Class I actions requiring top-of-desk escalation. The bulk of volume comes from two multi-SKU sterility clusters: K.C. Pharmaceuticals' private-label eye drop lines (distributed under ten-plus store brands) and Carolina Infusion LLC's compounded injectable portfolio (six separate lot recalls). Rounding out the list are a Cipla oral-solution impurity recall and a J&J biologic particulate-matter recall limited to Ohio distribution.

Ten store-brand labels trace to one Pomona, CA manufacturer — a single root-cause sterility failure propagating across the private-label supply chain. Pharmacy and retail partners should pull by lot regardless of label.

Companion recall to the lubricant line above, same firm and same day of initiation — indicative of a facility-wide sterility assurance gap rather than an isolated SKU defect.

Six separate compounded-injectable formulations from the same Ridgeland, SC compounder, all traced to the same equipment deficiency and all initiated on the same date. This is a facility-level sterility assurance failure spanning erectile-dysfunction mixes and a tirzepatide/B12 combination — prescribers using this compounder should confirm no inventory remains in circulation.

Narrow geographic footprint limits exposure, but particulate matter in an IV biologic warrants immediate quarantine of lot JNYJ1208 at affected Ohio infusion sites.